← All trials
NCT00876031
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2009
- Primary completion
- Jul 1, 2019
- Completion date
- Jul 1, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 320
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of TuebingenLead sponsor
- Cooperative Weichteilsarkom Study GroupCollaborator
- Gesellschaft fur Padiatrische Onkologie und Hamatologie - GermanyCollaborator
- Swiss Pediatric Oncology GroupCollaborator
- Deutsche KinderkrebsstiftungCollaborator
- Gesellschaft fur Padiatrische Onkologie und Hamatologie - AustriaCollaborator
- The Swedish Childhood Solid Tumor Working GroupCollaborator
- Polish Paediatric Solid Tumours Study GroupCollaborator
- University of UlmOverall official - principal investigator
- University of UlmStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.